
|Videos|May 20, 2022
Results of phase 3 PADRES trial of neoadjuvant axitinib in renal cell carcinoma
Author(s)Urology Times staff
Advertisement
Lead author Kevin Hakimi discusses the background and results of the study, “Interim analysis of
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












